---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-21-000050"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2021-07-29T23:59:59+00:00"
generated_at: "2026-06-30T00:43:15.523227+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q2 net sales $723.6M (+37.3%), EPS $2.47 (+104%); raises full-year guidance

## Summary
- Net sales $723.6M, up 37.3% (organic +30.6%); reported diluted EPS $2.47, up 104%.
- Adjusted diluted EPS $2.46, up 97%; Proprietary Products segment sales up 47%, driven by HVP components.
- Raises FY2021 net sales guidance to $2.760-$2.785B (from $2.630-$2.655B) and adjusted EPS to $8.05-$8.20 (from $6.95-$7.10).
- Strong demand from COVID-19 vaccines and base business; new capital spending tranche for HVP capacity expansion in 2022.

## SEC filing metadata
- accession: 0000105770-21-000050
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2021-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577021000050/0000105770-21-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577021000050/wst-20210729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-21-000050
- JSON: https://secwatch.observer/filing/0000105770-21-000050.json
- Plain text: https://secwatch.observer/filing/0000105770-21-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.